Search Result

Results for "

mGluRs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mGluR (167) Akt (4) Aminopeptidase (2) Apoptosis (3) Bacterial (1) Calcium Channel (5) CaMK (1) Caspase (1) CaSR (1) Endogenous Metabolite (7) ERK (5) GABA Receptor (3) iGluR (6) Mitochondrial Metabolism (1) nAChR (2) NF-κB (3) Phosphatase (1) PKC (3) Reference Standards (4) Src (1) Tau Protein (1) Trk Receptor (3)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (157)
Click Chemistry:	Alkynes (1)

171

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: mGluR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100372

E4CPG (RS)-ECPG	mGluR	Neurological Disease
E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation .

HY-101332

EGLU 1 Publications Verification (2S)-α-Ethylglutamic acid; (2S)-α-EGLU	mGluR	Neurological Disease
EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive *mGluR-2* receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a K_d value of 66 μM. EGLU is an antidepressant agent .

HY-103572

MNI137	mGluR	Neurological Disease
MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC₅₀s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization .

HY-103562

DMeOB 3,3'-Dimethoxybenzaldazine	mGluR	Neurological Disease
DMeOB (3,3'-Dimethoxybenzaldazine) is a *mGluR5* receptor negative allosteric modulator with an IC₅₀ of 3 μM. DMeOB displays reversible non-competitive inhibition of mGlu5-mediated responses .

HY-162232

mGluR2 agonist 1	mGluR	Neurological Disease
mGluR2 agonist 1 (Compound 5b) is a potent and selective metabotropic glutamate 2 receptor (mGluR) agonist with an EC₅₀ of 82 nM. mGluR2 agonist 1 can be used for the research of central nervous system (CNS) diseases .

HY-162232A

mGluR2 agonist 1 hydrochloride	mGluR	Neurological Disease
mGluR2 agonist 1 hydrochloride is a potent selective agonist for metabotropic glutamate receptors mGluR 2 with EC₅₀ of 82 nM .

HY-123411

MGS0039 BCI 632	mGluR	Neurological Disease
MGS0039 is a type II group *mGluR* antagonist. MGS0039 has a high affinity for mGluR2 and mGluR3, with K_i values of 2.2 nM and 4.5 nM, respectively. MGS0039 can attenuate the inhibitory effect of glutamate-induced cyclic AMP formation triggered by Forskolin (HY-15371) in CHO cells expressing mGluR2/mGluR3. MGS0039 shows antidepressant-like activity in rats .

HY-19434A

cis-ACPD	iGluR mGluR	Neurological Disease
cis-ACPD is a potent agonist of NMDA receptor, with an IC₅₀ of 3.3 μM. cis-ACPD is also a selective agonist of group II mGluR, with EC₅₀s of 13 μM and 50 μM for *mGluR2* and *mGluR4*, respectively .

HY-100838A

L-CCG-I	mGluR	Metabolic Disease
L-CCG-I is an extended isomer of conformationally restricted glutamate analog. L-CCG-I also is a potent agonist for *mGluR2* with an EC₅₀ value of 0.3 nM. L-CCG-I can be used for the research of mGluR family .

HY-108546

L-AP3 3-Phosphono-L-alanine	mGluR	Neurological Disease
L-AP3, metabotropic glutamate receptor (mGluR) antagonist, inhibits D-phosphoserine and L-phosphoserine with IC₅₀s of 368 μM and 2087 μM, respectively .

HY-103560

(S)-HexylHIBO	mGluR	Neurological Disease
(S)-HexylHIBO is the S-enantiomer of HexylHIBO. HexylHIBO is a group I *mGluR* antagonist. HexylHIBO elevates the hypothalamus-pituitary-adrenal axis response to restraint in rats. HexylHIBO is promising for research of central nervous system-related diseases .

HY-103552

LY487379 hydrochloride	mGluR	Neurological Disease
LY487379 hydrochloride is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 hydrochloride potentiates glutamate-stimulated [ ³⁵S]GTPγS binding with EC₅₀ values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 hydrochloride promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 hydrochloride can be used for schizophrenia research .

HY-122255

LY487379	mGluR	Neurological Disease
LY487379 is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 potentiates glutamate-stimulated [ ³⁵S]GTPγS binding with EC₅₀ values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 can be used for schizophrenia research .

HY-107481

Fasoracetam NS 105	mGluR	Neurological Disease
Fasoracetam (NS 105) is the activator of metabotropic glutamate receptor (mGluR). Fasoracetam (NS 105) has the potential for the research of attention-deficit hyperactivity disorder (ADHD) and Alzheimer's disease (AD) .

HY-169808

BOMA	mGluR	Neurological Disease
BOMA (Compound 7) is a potent and selective metabotropic glutamate receptor 5 (mGluR 5) antagonist with an IC₅₀ value of 3 nM and an K_i value of 3 nM. BOMA is promising for research of various pain states, including acute, persistent and chronic pain, inflammatory pain and neuropathic pain .

HY-15129

O-Phospho-L-serine 2 Publications Verification L-Serine O-phosphate; L-SOP	mGluR Endogenous Metabolite	Neurological Disease
O-Phospho-L-serine is the immediate precursor to L-cystein in the serine synthesis pathway, and an agonist at the *group III mGluR* receptors** (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for *mGluR1* and a potent antagonist for *mGluR2* .

HY-100804

L-Cysteinesulfinic acid	mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-W017230

L-Cysteinesulfinic acid monohydrate	mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-100840

(S)-4C3HPG (S)-4-Carboxy-3-hydroxyphenylglycine	mGluR	Neurological Disease
(S)-4C3HPG ((S)-4-Carboxy-3-hydroxyphenylglycine) is an antagonist of *metabotropic glutamate receptor 1a (mGluR* 1a) and an agonist of GluR2**. (S)-4C3HPG has the anticonvulsant activity and protects against audiogenic seizures in DBA/2 mice .

HY-158376

mGluR7-IN-1	mGluR	Neurological Disease
mGluR7-IN-1 (compound 2Z) is a *mGluR3* inhibitor .

HY-100804R

L-Cysteinesulfinic acid (Standard)	Reference Standards mGluR Endogenous Metabolite	Neurological Disease
L-Cysteinesulfinic acid (Standard) is the analytical standard of L-Cysteinesulfinic acid. This product is intended for research and analytical applications. L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-50906

LY404039 2 Publications Verification	mGluR	Neurological Disease
LY404039 is a potent, selective and orally active *mGluR2* and *mGluR3* agonist with K_is of 149 nM and 92 nM for recombinant human mGluR2 and *mGluR3, respectively. LY404039 shows >100-fold selectivity for mGluR*2/3 over other receptors/transproters. LY404039 has antipsychotic and anxiolytic effects .

HY-15129S

O-Phospho-L-serine-13C3,15N L-Serine O-phosphate-¹³C₃,¹⁵N; L-SOP-¹³C₃,¹⁵N	mGluR Endogenous Metabolite	Neurological Disease
O-Phospho-L-serine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled O-Phospho-L-serine. O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2 .

HY-15129R

O-Phospho-L-serine (Standard) L-Serine O-phosphate (Standard); L-SOP (Standard)	mGluR Endogenous Metabolite	Neurological Disease
O-Phospho-L-serine (Standard) (L-Serine O-phosphate (Standard)) is the analytical standard of O-Phospho-L-serine (HY-15129). This product is intended for research and analytical applications. O-Phospho-L-serine is the immediate precursor to L-cystein in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8). O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2.

HY-141832

mGluR5 modulator 1	mGluR	Neurological Disease
mGluR5 modulator 1 is a *mGluR5* positive allosteric modulator. mGluR5 modulator 1 can be used for the research of the schizophrenia and cognitive impairments .

HY-14612

CPPHA	mGluR	Neurological Disease
CPPHA is potent and selective positive allosteric modulator (PAM) of the *mGluR5* and *mGluR1* (metabotropic glutamate receptor). CPPHA can potentiate responses of mGluR5 and mGluR1 to activation of these receptors. CPPHA is developed for the research of central nervous system disorders .

HY-155352

mGluR5 antagonist-1	mGluR	Neurological Disease
mGluR5 antagonist-1 is an orally active *mGluR5* antagonist with an IC₅₀ value of 11.5 nM. mGluR5 antagonist-1 has anti-depressant effect. mGluR5 antagonist-1 can be used for the study of depressive disorder .

HY-110190

VU0422288 ML396	mGluR	Neurological Disease
VU0422288 (ML396) is a positive allosteric modulator of group III *mGluRs. VU0422288 inhibits mGluRs* with EC₅₀s of 125 nM, 146 nM, and 108 nM for *mGluR4, mGluR7, and mGluR8*, respectively in calcium mobilization assays. VU0422288 reverses deficits in contextual fear memory, social recognition, and apneas in Rett syndrome (RTT) model mice .

HY-121623

VU0359516	Others	Others
VU0359516 is a compound that modulates mGluR4 activity, obtained through structure-activity relationship analysis of mGluR4 positive allosteric modulators, with improved potency and efficacy, as well as selectivity for mGluR4.

HY-147530

mGluR2 modulator 4	mGluR	Neurological Disease
mGluR2 modulator 4 (compound 47) is a potent *mGluR2* positive allosteric modulator with an EC₅₀ value of 0.8 μM. mGluR2 modulator 4 can be used for researching antipsychotic .

HY-153132

mGluR3 modulator-1	mGluR	Metabolic Disease
mGluR3 modulator-1 (compound 3) is a *mGluR3* modulator, with an EC₅₀ of 1-10 μM in HEK293T-mGluR-Gqi5 Calcium Mobilization Assay .

HY-16766

Decoglurant RO4995819	mGluR	Neurological Disease
Decoglurant (RO4995819) is a negative allosteric modulator of *mGluR2* and *mGluR3*. Decoglurant is developed as an antidepressant .

HY-147528

mGluR2 modulator 2	mGluR	Neurological Disease
mGluR2 modulator 2 (compound 2) is a potent, selective and orally bioavailable *mGluR2* positive allosteric modulator with an EC₅₀ value of 0.13 μM. mGluR2 modulator 2 can be used for researching antipsychotic .

HY-131286A

Talaglumetad hydrochloride LY-544344 hydrochloride	mGluR	Neurological Disease
Talaglumetad hydrochloride is a precursor of thetype II metabotropic glutamate receptor (mGluR2/3) agonist Eglumegad for the research of anxiety.

HY-100405

FTIDC	mGluR	Neurological Disease
FTIDC is an orally active, noncompetitive, selective allosteric *metabotropic glutamate receptor (mGluR) 1* antagonist with an IC₅₀ of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1 .

HY-130630

mGluR2 modulator 1	mGluR	Neurological Disease
mGluR2 modulator 1 (compound 95) is a potent and BBB-penetrated *mGluR2* (metabotropic glutamate receptor-2) positive allosteric modulator, with an EC₅₀ of 0.03 μM. mGluR2 modulator 1 can be used for psychosis research .

HY-18654

ADX88178 1 Publications Verification	mGluR	Neurological Disease
ADX88178 is a potent metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) with an EC₅₀ of 4 nM for human mGluR4.

HY-147529

mGluR2 modulator 3	mGluR	Neurological Disease
mGluR2 modulator 3 (compound 1) is a potent *mGluR2* positive allosteric modulator with an EC₅₀ value of 0.87 μM. mGluR2 modulator 3 has activity in psychosis disease models such as methamphetamine-induced hyperactivity and mescaline-induced scratching in mice .

HY-119282

AZD6538	mGluR	Neurological Disease
AZD6538 is a potent, selective and brain penetrant mGluR5 negative allosteric modulator. AZD6538 inhibits DHPG (HY-12598A)-stimulated intracellular Ca2+ release in HEK cells expressing rat or human mGluR5, with IC₅₀ values of 3.2 and 13.4 nM for rat mGluR5 and human mGluR5, respectively. AZD6538 can be used for the research of neuropathic pain .

HY-11095

NPS 2390	mGluR CaSR	Cardiovascular Disease Neurological Disease
NPS 2390 is a noncompetitive antagonist of mGluR1 and mGluR5 . NPS 2390 is also a potent CaSR (calcium-sensing receptor) inhibitor .

HY-133555

mGluR2 antagonist 1	mGluR	Neurological Disease
mGluR2 antagonist 1 is a highly potent, orally bioavailable and selective class of *mGluR2* negative allosteric modulator (IC₅₀ of 9 nM) with excellent brain permeability .

HY-117132

YM-202074	mGluR	Neurological Disease
YM-202074 is a selective, allosteric metabotropic glutamate receptor type 1 (mGluR1) antagonist with high affinity. YM-202074 binds to the allosteric site of rat *mGluR1* with a K_i of 4.8 nM. YM-202074 fumarate also inhibits *mGluR1*-mediated inositol phosphate production in rat cerebellar granule cells with an IC₅₀ of 8.6 nM. YM-202074 has potent neuroprotective effects in transient MCA (tMCA) occlusion rat models .

HY-103556

YM-202074 fumarate	mGluR	Neurological Disease
YM-202074 fumarate is a selective, allosteric metabotropic glutamate receptor type 1 (mGluR1) antagonist with high affinity. YM-202074 fumarate binds to the allosteric site of rat *mGluR1* with a K_i of 4.8 nM. YM-202074 fumarate also inhibits *mGluR1*-mediated inositol phosphate production in rat cerebellar granule cells with an IC₅₀ of 8.6 nM. YM-202074 fumarate has potent neuroprotective effects in transient MCA (tMCA) occlusion rat models .

HY-12598A

DHPG 4 Publications Verification (RS)-3,5-DHPG	mGluR	Neurological Disease
DHPG is the agonist for mGluR 1/5 (EC₅₀ for mGluR 1 is 60 nM) that activates the phospholipase C (PLC) pathway, and leads ultimately to the activation of protein kinase C (PKC) .

HY-12598

(S)-3,5-DHPG	mGluR	Neurological Disease
(S)-3,5-DHPG is a weak, but selective group I metabotropic glutamate receptors (mGluRs) agonist with K_i values of 0.9 μM and 3.9 μM for mGluR1a and mGluR5a, respectively . (S)-3,5-DHPG exhibits anxiolytic activity in rats subjected to hypoxia .

HY-162860

FO-4-15	mGluR CaMK Tau Protein	Neurological Disease
FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H₂O₂ in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage .

HY-103561

DCB	mGluR	Neurological Disease
DCB (3,3′-dichlorobenzaldazine) is an neutral allosteric modulator of themetabotropic glutamate receptor metabotropic glutamate receptor subtype 5 (mGluR5) . DCB blocks the positive allosteric regulation of mGluRs (mGluR5) with the help of 3,3′-difluorobenzaldazine (DFB). DCB shows the negative modulatory effect of 3,3′-dimethoxybenzaldazine (DMeOB) .

HY-168028

mGluR2 modulator 5	mGluR	Neurological Disease
mGluR2 modulator 5 (Compound 11) is an orally active, selective *mGluR2* negative allosteric modulator with an IC₅₀ of 8.9 nM. Pharmacokinetic studies in rats show that mGluR2 modulator 5 can effectively cross the blood-brain barrier. It can modulate cognitive and neurological functions in mood disorders and is suitable for research in the field of neurodegenerative diseases .

HY-103564

ACDPP	mGluR	Neurological Disease
ACDPP is a specific *mGluR5* antagonist. ACDPP partially bolcks the increase of fragile X mental retardation protein (FMRP) caused by DHPG (HY-12598A) (group I mGluR Agonist) .

HY-110122

AZ 12216052 1 Publications Verification	mGluR	Neurological Disease
AZ 12216052 is a *mGluR8* positive allosteric modulator, and helps *mGluR8* modulate signaling inputing to retinal ganglion cells. AZ 12216052 exhibits antianxiety effect .

Cat. No.	Product Name

HY-L006

GPCR/G Protein Compound Library

2,895 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provides a unique collection of 2,895 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15129

O-Phospho-L-serine 2 Publications Verification L-Serine O-phosphate; L-SOP	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite	mGluR Endogenous Metabolite
O-Phospho-L-serine is the immediate precursor to L-cystein in the serine synthesis pathway, and an agonist at the *group III mGluR* receptors** (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for *mGluR1* and a potent antagonist for *mGluR2* .

HY-100804

L-Cysteinesulfinic acid	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	mGluR Endogenous Metabolite
L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-W017230

L-Cysteinesulfinic acid monohydrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	mGluR Endogenous Metabolite
L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

HY-100786

DL-AP3	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite mGluR Phosphatase
DL-AP3 is a competitive *mGluR1* and *mGluR5* antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect .

HY-12597

Quisqualic acid L-Quisqualic acid	Structural Classification Ketones, Aldehydes, Acids Combretaceae Source classification Plants Quisqualis indica Linn.	iGluR mGluR
Quisqualic acid (L-Quisqualic acid), a natural analog of glutamate, is a potent and pan two subsets (iGluR and *mGluR) of excitatory amino acid (EAA) agonist with an EC₅₀* of 45 nM and a K_i of 10 nM for mGluR1R. Quisqualic acid is isolated from the fruits of Quisqualis indica .

HY-W015546

β-N-methylamino-L-alanine hydrochloride 1 Publications Verification BMAA hydrochloride	Structural Classification Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	Bacterial mGluR PKC
β-N-methylamino-L-alanine hydrochloride (BMAA hydrochloride) is a neurotoxin produced by cyanobacteria. β-N-methylamino-L-alanine hydrochloride activates *mGluR3* and inhibits PKC. β-N-methylamino-L-alanine hydrochloride can be used in the research of neurodegenerative diseases and immune diseases .

HY-100804R

L-Cysteinesulfinic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards mGluR Endogenous Metabolite
L-Cysteinesulfinic acid (Standard) is the analytical standard of L-Cysteinesulfinic acid. This product is intended for research and analytical applications. L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively .

Cat. No.	Product Name	Chemical Structure

HY-15129S

O-Phospho-L-serine-13C3,15N
O-Phospho-L-serine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled O-Phospho-L-serine. O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2 .

Cat. No.	Product Name		Classification

HY-118022

VU0361747		Alkynes
VU0361747 is a potent and selective positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4 PAM). VU0361737 has neuroprotective effect. VU0361737 significantly reverses Amphetamine-induced hyperlocomotion in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks